798543-64-3

Upstream product

• 798543-46-1 3-[1-(2,4-dimethoxybenzyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]propionic acid methyl ester 
• 959931-08-9 C₁₆H₁₈N₂O₅ 
• 93633-32-0 5-methoxy-2-methylene-5-oxopentanoic acid 
• 798543-44-9 N-(but-3-enyl)-(2,4-dimethoxybenzyl)amine 
• 798543-45-0 4-[but-3-enyl-(2,4-dimethoxybenzyl)carbamoyl]pent-4-enoic acid methyl ester 
• 20781-20-8 2,4-Dimethoxybenzylamine 
• 1343858-78-5 C₁₁H₁₄N₂O₂ 
• 959931-17-0 C₁₈H₂₂N₂O₅ 
• 7409-30-5 p-nitrobenzylamine 

Downstream Products

• 798543-65-4 3-[1-(4-acetylamino-benzyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-propionic acid methyl ester 
• 798543-63-2 3-[1-(4-acetylamino-benzyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-N-hydroxy-propionamide 
• 798543-66-5 C₂₂H₂₃N₃O₄ 

Relevant academic research and scientific papers

Modification of cap group in δ-lactam-based histone deacetylase (HDAC) inhibitors

Novel δ-lactam-based HDAC inhibitors which have various substituted benzyl, bi-aromatic cap groups were prepared using ring closure metathesis reaction, and evaluated their HDAC inhibitory activities and anti-proliferative effects. Among prepared analogue

NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention is related to new 2-oxo-cyclic compound the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the inflammatory